ZMIZ1 enhances ERα-dependent expression of E2F2 in breast cancer
Journal of Molecular Endocrinology · 02.04.2024 · 73 (1)
DOI: 10.1530/jme-23-0133 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Molecular Endocrinology, erschienen am 02.04.2024. Verfasst von Weiye Zhao und 15 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biology, University of York, York, UK. Hauptthemen laut MEDLINE: Breast Neoplasms, Estrogen Receptor alpha, Gene Expression Regulation, Neoplastic, E2F2 Transcription Factor. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 48 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
The estrogen receptor-α (ER) drives 75% of breast cancers. On activation, the ER recruits and assembles a 1–2 MDa transcriptionally active complex. These complexes can modulate tumour growth, and understanding the roles of individual proteins within these complexes can help identify new therapeutic targets. Here, we present the discovery of ER and ZMIZ1 within the same multi-protein assembly by quantitative proteomics, and validated by proximity ligation assay. We characterise ZMIZ1 function by demonstrating a significant decrease in the proliferation of ER-positive cancer cell lines. To establish a role for the ER-ZMIZ1 interaction, we measured the transcriptional changes in the estrogen response post-ZMIZ1 knockdown using an RNA-seq time-course over 24 h. Gene set enrichment analysis of the ZMIZ1-knockdown data identified a specific delay in the response of estradiol-induced cell cycle genes. Integration of ENCODE data with our RNA-seq results identified that ER and ZMIZ1 both bind the promoter of E2F2. We therefore propose that ER and ZMIZ1 interact to enable the efficient estrogenic response at subset of cell cycle genes via a novel ZMIZ1–ER–E2F2 signalling axis. Finally, we show that high ZMIZ1 expression is predictive of worse patient outcome, ER and ZMIZ1 are co-expressed in breast cancer patients in TCGA and METABRIC, and the proteins are co-localised within the nuclei of tumour cell in patient biopsies. In conclusion, we establish that ZMIZ1 is a regulator of the estrogenic cell cycle response and provide evidence of the biological importance of the ER–ZMIZ1 interaction in ER-positive patient tumours, supporting potential clinical relevance.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Biology, University of York, York, UK.
- CRUK Cambridge Institute, University of Cambridge, Cambridge, UK.
- Department of Cancer Immunology and Virology, Dana-Farber Cancer Institute, Smith Building, Boston, Massachusetts, USA.
- The Institute of Metabolism and Systems Research (IMSR), University of Birmingham, College of Medical and Dental Sciences, Birmingham, UK.
- Chris O'Brien Lifehouse, Sydney, New South Wales, Australia.
- Department of Pharmacy and Biotechnology, University of Bologna, Bologna, Italy.
ORCID-Profile: Andrew N Holding
Zitieren
APA
Zhao, W., Rose, S. F., Blake, R., Godicelj, A., Cullen, A. E., Stenning, J., Beevors, L., Gehrung, M., Kumar, S., Kishore, K., Sawle, A., Eldridge, M., Giorgi, F. M., Bridge, K. S., Markowetz, F., & Holding, A. N. (2024). ZMIZ1 enhances ERα-dependent expression of E2F2 in breast cancer. Journal of Molecular Endocrinology, 73(1). https://doi.org/10.1530/jme-23-0133
Vancouver
Zhao W, Rose SF, Blake R, Godicelj A, Cullen AE, Stenning J, et al. ZMIZ1 enhances ERα-dependent expression of E2F2 in breast cancer. Journal of Molecular Endocrinology. 2024;73(1). doi:10.1530/jme-23-0133
BibTeX
@article{Zhao2024,
author = {Zhao, Weiye and Rose, Susanna F and Blake, Ryan and Godicelj, Aňze and Cullen, Amy E and Stenning, Jack and Beevors, Lucy and Gehrung, Marcel and Kumar, Sanjeev and Kishore, Kamal and Sawle, Ashley and Eldridge, Matthew and Giorgi, Federico M and Bridge, Katherine S and Markowetz, Florian and Holding, Andrew N},
title = {ZMIZ1 enhances ERα-dependent expression of E2F2 in breast cancer},
journal = {Journal of Molecular Endocrinology},
year = {2024},
volume = {73},
number = {1},
doi = {10.1530/jme-23-0133}
}
EUVIMED